Invivyd Updates VYD2311 REVOLUTION Trials, Modestly Upsizes Study, Unveils Measles mAb VMS-063 [Yahoo! Finance]
Invivyd, Inc. (IVVD)
Company Research
Source: Yahoo! Finance
the discovery and early development work for a measles monoclonal antibody candidate, VMS-063, during a conference call led by board chairman Marc Elia alongside Chief Scientific Officer Dr. Robert Allen and Chief Medical Officer Dr. Michael Mina. Company frames monoclonal antibodies as an alternative to vaccines for vulnerable populations Elia argued that SARS-CoV-2 continues to transmit broadly in the U.S., with periodic waves that contribute to “lifespan-shortening” damage. He said Invivyd's goal is to develop monoclonal antibodies that could serve as a more durable and immediate form of protection than vaccination, describing antibodies as “immediate, equitable, non-inflammatory or reactogenic,” and “free of spike protein,” which he characterized as “an important inflammatory and fundamentally toxic antigen.” ? AMC's Easter Surprise: A Bullish New Act? Elia also pointed to Invivyd's currently authorized COVID-19 antibody, pemivibart (PEMGARDA), as proof of concept for “dur
Show less
Read more
Impact Snapshot
Event Time:
IVVD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IVVD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IVVD alerts
High impacting Invivyd, Inc. news events
Weekly update
A roundup of the hottest topics
IVVD
News
- Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care SummitGlobeNewswire
- Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of MeaslesGlobeNewswire
- Invivyd Launches “Antibodies for Any Body” in Partnership with World Champion Skier Lindsey Vonn to Inspire Actions that Help Support Immune HealthGlobeNewswire
- Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Invivyd Announces Presentation at the World Vaccine Congress WashingtonGlobeNewswire
IVVD
Earnings
- 3/5/26 - Miss
IVVD
Sec Filings
- 4/9/26 - Form 8-K
- 4/6/26 - Form ARS
- 4/6/26 - Form DEFA14A
- IVVD's page on the SEC website